Treatment of the acute severe pulmonary embolism using endovascular methods.

PURPOSE: To present a single-centre experience with endovascular treatment of patients with severe symptoms secondary to acute pulmonary embolism (PE).
MATERIAL AND METHODS: Twenty-five patients were treated due to contraindications or deficient effects of systemic thrombolytic therapy. The patients were treated with a combination of fragmentation and aspiration, only aspiration, or only fragmentation, and with catheter-directed thrombolytic therapy.
RESULTS: The saturation was improved following treatment in all patients, except in one where the procedure could not be completed. There were no immediate or late procedure-related complications.
CONCLUSIONS: Endovascular treatment of severe PE is a safe and efficient option in patients with failing effect or contraindication to systemic thrombolysis.

Introduction

Acute pulmonary embolism (PE) is a severe condition with a high risk of mortality. The severity of symptoms may vary, but most often include dyspnoea, chest pain, cough, and in some cases haemoptysis. Unstable patients are presented with a drop in blood pressure (BP) and tachycardia, and untreated they may progress to circulatory collapse [1]. Following clinical examination and laboratory tests the diagnosis is commonly verified by echocardiography (ECO) and/or computer tomography (CT). A pulmonary angiography (PAI) and pulmonary ventilation/perfusion scan may be performed in specialised hospitals [2-4].

Haemodynamically unstable patients are traditionally treated with systemic thrombolysis or open embolectomy [5]. However, there are several contraindications for thrombolysis, for instance current or threatening bleeding, stroke, recent surgery or delivery, trauma, or malignant diseases.

For patients with contraindications or insufficient effect of systemic thrombolysis, endovascular treatment may be an option [5-11]. Endovascular methods include catheter-directed administration of thrombolytics (CDT), fragmentation and/or aspiration of emboli, or a combination of these methods. An inferior vena cava (IVC) filter is often placed to prevent further embolisation [12-19].

We retrospectively present our results of the endovascular treatment in 25 patients with acute, severe PE.

Material and methods

Of the 25 patients, 17 were male and eight female, age range 31-83 years. The treatment was performed due to contraindications including gastro-intestinal (G-I) bleeding (n = 2), malignancy (n = 4), stroke (n = 3), recent surgery (n = 3), risk of bleeding (n = 3), recent cardio-pulmonary resuscitation (n = 1), migrating thrombus, and insufficient effect of systemic thrombolysis (n = 8) (Table 1).

Table 1

Patients and treatments

Patient no.	Age	Gender	History/Actual problem	Indication for endovascular treatment	IVC filter	Endovascular treatment
1	58	M	Pulmonary transplant	Recent surgery	Yes	CDT
2	64	M	Liver malignancy	Recent surgery	Yes	A
3	69	M	Chest pain + cardiac arrest	Insufficient effect of systemic thrombolysis	No	F + A
4	70	M	Intracranial haemorrhage	Stroke	Yes	F + A
5	70	F	Chest pain	Risk of bleeding (aorta aneurysm)	Yes	F + A
6	79	M	Pneumonia + sepsis	Insufficient effect of systemic thrombolysis	No	F
7	42	M	Urachus malignancy	Malignancy	Yes	A
8	58	F	Leiomyosarcoma	Malignancy	No	F + A + CDT
9	72	M	Dyspnoea	Migrating thrombus	No	F + A
10	68	F	Dyspnoea	GI-bleeding	Yes	F
11	68	F	Cardiac arrest	Recent CPR	Yes	F + A
12	66	M	Cerebral malignancy	GI-bleeding	Yes	F + A
13	78	M	Dyspnoea	Insufficient effect of systemic thrombolysis	No	F + A
14	63	F	Stroke + cardiac arrest	Stroke	Yes	F + A
15	82	M	Dyspnoea	Insufficient effect of systemic thrombolysis	No	F + CDT
16	71	M	Dyspnoea	Insufficient effect of systemic thrombolysis	Yes	F + A
17	61	M	Pancreatic malignancy	Malignancy	No	F
18	64	M	Intracranial haemorrhage	Stroke	Yes	A
19	69	M	Pneumonia + deep vein thrombosis	Risk of bleeding (infection)	Yes	F + A
20	57	M	Chest pain + dyspnoea	Risk of bleeding (after coronary a i)	Yes	F
21	69	F	Dyspnoea	Malignancy	Yes	F + A
22	43	F	Dyspnoea	Insufficient effect of systemic thrombolysis	Yes	A
23	74	M	Intracranial surgery	Recent surgery	Yes	F + A
24	31	F	Recent delivery	Insufficient effect of systemic thrombolysis	No	F + A
25	63	M	Dyspnoea + cardiac arrest	Insufficient effect of systemic thrombolysis	Yes	F + A

A – aspiration, CDT – catheter-directed therapy, CPR – cardio pulmonary resuscitation, F – fragmentation

Ten patients presented at the emergency department with dyspnoea and five with chest pain/cardiac arrest. The remaining patients were hospitalised at the time of acute PE due to malignancy, stroke, or palliation. Five patients were haemodynamically unstable with SBP< 90 at the time of the procedure. The saturation was moderate or severely decreased in all patients, measuring between 69 and 97% (mean 86%) with oxygen support. The respiratory frequency was measured in 19 patients, with a mean value of 23/min.

Echocardiography (ECO) was performed in 20 patients, and 19 or them had signs of right heart strain. The extent of the PE was verified by CT scans in all patients. The Miller Index was used to quantify pulmonary arterial obstruction, with a mean value of 14.6 (patient number = 11, 12, 13, 14, 15, 20).

All procedures except one were performed with local anaesthesia, with continuous monitoring of BP, heart rate, and saturation. Following puncture of the right common femoral vein, an IVC filter (Celect, Cook Sweden AB, Askim, Sweden) was positioned in the infrarenal IVC if indicated, to prevent further embolisation. Thereafter, a 70 cm long 9 F introducer was placed with the tip in the IVC close to the right atrium. The tip of a 7 F APC catheter (Cook Sweden AB) was thereafter advanced through the introducer to the left and right main pulmonary arteries and diagnostic angiograms were performed. Subsequently the introducer tip was advanced over a Glidewire (Terumo Sweden AB, Västra Frölunda, Sweden) to the main pulmonary trunk. In cases with occlusive central emboli fragmentation attempt was done using rotation of the tip of a 5 F pigtail catheter (Cordis, Sollentuna, Sweden) placed over the guidewire in the left and/or right pulmonary artery. Following exchange of the guidewire to a 0.018 wire (Boston Scientific, Helsingborg, Sweden), an Arrow- Trerotola positioned over the wire percutaneous thrombolytic device (PTD – Arrow Int. Inc., Reading PA, USA) [20] was advanced into the pulmonary trunk, and fragmentation of the emboli in the main and segmental branches was performed. Aspiration of emboli was done using an 8 F JR4 guiding catheter (Cordis). In three patients CDT was administrated though a 4 F Cobra C2 catheter (Cordis) or a 4 F MPA catheter (Terumo) placed with the tip in the embolus in the main right or left pulmonary artery, using alteplase (Actilyse, Boerhinger Ingelheim AB, Stockholm, Sweden). The results of all the treatments were verified during the procedure by multiple contrast injections and by final angiography (Figure 1A-C).

Figure 1

A) Emboli in the right pulmonary artery causing perfusion defects. B) Arrow-Trerotola in place in the artery to the lower lobe. C) Result after the endovascular treatment with improvement of the perfusion

Results

One patient in severe, unstable condition and with extensive PE expired during the attempted fragmentation due to circulatory arrest that could not be reversed. The procedures were successfully completed in the other 24 patients. In 17 patients an IVC filter was placed during the procedure. In 14 of the 23 patients fragmentation and aspiration of the emboli were performed (Figure 2). In four patients aspiration only and in another four fragmentation only was performed. CDT alone was performed in one patient, in whom mechanical or systemic treatment was contraindicated due to recent surgery (patient 1). In two other patients, CDT was combined with mechanical removal (patient 8 and 15) due to large emboli burden.

Figure 2

Aspirated emboli

The final angiography showed improved flow in the pulmonary circulation in all patients. One of these patients was, however, subsequently treated by surgical embolectomy due to recurrent circulatory instability. The treatment had good primary effect with immediate improvement of saturation in all the other patients, and there were no procedure-related complications (Table 1).

The mean time of hospitalisation after the procedure was 12.5 days, including less than half a day of observation in the intensive care unit.

During follow-up (up to 42 months) nine patients expired. One died due to pneumonitis after three days, and one due to anoxia of the brain following heart arrest (reversed prior to the procedure) after 12 days. One patient expired due to aortic dissection more than one year after treatment, two due to unknown causes after more than six months, and the others later due to underlying disorders.

Discussion

Acute PE is a severe condition with substantial morbidity and mortality (15-18%) within the first three months [21]. Late complications such as chronic thromboembolic pulmonary hypertension may cause significant morbidity [22]. The traditional treatment includes anticoagulant therapy in haemodynamically stable patients, while unstable patients are treated with systemic thrombolysis or open surgery. Open surgery is an extensive procedure that carries substantial risk of complications [12]. Systemic thrombolysis usually has good effect but contains risks and contraindications, such as ongoing or expected bleeding, recent stroke, trauma, surgery or delivery, known gastrointestinal ulceration, and some malignant diseases.

Endovascular treatment of patients with massive PE was reported previously [6-12]. There are several strategies of endovascular treatment. A widely used therapy is CDT, where the thrombolytic agent is administrated directly into the embolus, with a potent local effect [12,13]. A percutaneous central PE fragmentation may be done using rotation of, for example, a pigtail catheter. The smaller fragments migrate more peripherally, increasing total pulmonary perfusion and relieving right ventricular afterload, and may augment the effect of the thrombolysis [12,14]. Several different aspiration devices are available, some with combined fragmentation with drug infusion-function [13,15]. Ultrasound-assisted catheter-directed thrombolysis is another relatively new method, but one that requires treatment lasting about 20 hours [16-19]. We retrospectively report our experience of interventional treatment of patients with severe symptoms secondary to massive PE, in which conventional treatment failed or could not be performed.

All our patients were severely symptomatic, and systemic thrombolysis was contraindicated or unsuccessful in all of them. Due to the urgency of the procedures registration of the different parameters such as pulmonary artery pressure was not performed. The procedures had, however, a primary prompt effect with substantial improvement of saturation, which persisted during the patients’ hospital stay.

Mechanical fragmentation of the PE using intravascular methods and devices was previously described [12]. The Arrow-Trerotola PTD is relatively common in the treatment of thrombosed dialysis grafts [20] but may also be used in native fistulas [23] and in peripheral veins [24]. However, to our knowledge use of this device in the treatment of PE was not previously reported. For aspiration of the embolic material we used cardiac guiding catheters due to their large inner lumen and good torque ability, allowing easy positioning in more peripheral branches.

There were no procedure-related complications. Most of our patients had PE secondary to severe underlying diseases, which was the main cause of the prolonged hospital stay after intervention. The causes of deaths were not related to the procedures.

We conclude that the treatment of the acute PE using our methods is safe and efficient in the majority of patients and may be recommended.

Conflict of interest

The authors report no conflict of interest.